Free Trial

Mineralys Therapeutics (MLYS) Competitors

Mineralys Therapeutics logo
$14.98 +0.50 (+3.42%)
As of 02:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MLYS vs. RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, SRRK, VKTX, and PTGX

Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Scholar Rock (SRRK), Viking Therapeutics (VKTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

Mineralys Therapeutics vs. Its Competitors

Mineralys Therapeutics (NASDAQ:MLYS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Mineralys Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mineralys TherapeuticsN/AN/A-$177.81M-$3.73-4.02
Ultragenyx Pharmaceutical$560.23M4.93-$569.18M-$5.88-4.97

Mineralys Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Mineralys Therapeutics' return on equity of -71.15% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Mineralys TherapeuticsN/A -71.15% -65.71%
Ultragenyx Pharmaceutical -93.04%-186.49%-36.81%

In the previous week, Ultragenyx Pharmaceutical had 37 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 38 mentions for Ultragenyx Pharmaceutical and 1 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.32 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Mineralys Therapeutics Positive
Ultragenyx Pharmaceutical Neutral

Mineralys Therapeutics presently has a consensus target price of $32.25, suggesting a potential upside of 115.22%. Ultragenyx Pharmaceutical has a consensus target price of $83.64, suggesting a potential upside of 186.39%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Mineralys Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mineralys Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Ultragenyx Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

Mineralys Therapeutics has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Ultragenyx Pharmaceutical beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLYS vs. The Competition

MetricMineralys TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$977.83M$2.96B$5.54B$9.13B
Dividend YieldN/A2.43%5.06%4.01%
P/E Ratio-4.0221.2228.2819.58
Price / SalesN/A186.65373.3579.96
Price / CashN/A41.0524.7227.50
Price / Book3.907.728.265.55
Net Income-$177.81M-$55.05M$3.19B$252.28M
7 Day Performance10.75%12.50%5.27%2.99%
1 Month Performance4.64%13.41%9.19%11.65%
1 Year Performance3.49%4.02%30.12%17.15%

Mineralys Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLYS
Mineralys Therapeutics
2.3555 of 5 stars
$14.99
+3.4%
$32.25
+115.2%
+0.1%$977.83MN/A-4.0228Positive News
Gap Down
RARE
Ultragenyx Pharmaceutical
4.4048 of 5 stars
$39.61
-0.8%
$87.00
+119.6%
-34.6%$3.77B$560.23M-6.741,294Trending News
Analyst Forecast
Analyst Revision
Gap Down
AAPG
Ascentage Pharma Group International
N/A$42.04
-1.9%
N/AN/A$3.73B$134.35M0.00600News Coverage
Gap Down
MRUS
Merus
1.916 of 5 stars
$52.58
-2.3%
$84.64
+61.0%
-4.8%$3.73B$36.13M-12.8937Analyst Upgrade
Insider Trade
ACLX
Arcellx
2.561 of 5 stars
$65.55
-2.4%
$111.23
+69.7%
+10.5%$3.70B$107.94M-21.9280Positive News
SWTX
SpringWorks Therapeutics
1.5801 of 5 stars
$46.99
flat
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230Positive News
RNA
Avidity Biosciences
2.1854 of 5 stars
$28.80
-1.3%
$65.59
+127.7%
-29.8%$3.52B$10.90M-9.60190Analyst Forecast
Gap Up
ACAD
ACADIA Pharmaceuticals
4.705 of 5 stars
$20.88
-0.3%
$27.88
+33.5%
+18.1%$3.51B$957.80M15.24510Positive News
Analyst Revision
SRRK
Scholar Rock
3.7289 of 5 stars
$35.48
-1.4%
$42.67
+20.3%
+311.4%$3.42B$33.19M-14.02140
VKTX
Viking Therapeutics
4.5754 of 5 stars
$27.51
-2.4%
$87.15
+216.8%
-45.6%$3.17BN/A-23.9220Positive News
PTGX
Protagonist Therapeutics
1.5957 of 5 stars
$49.87
-2.3%
$66.10
+32.5%
+46.7%$3.16B$434.43M66.49120Positive News

Related Companies and Tools


This page (NASDAQ:MLYS) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners